ADSTILADRIN Early Utilization and Outcomes in the Real World Setting (ABLE-41)

Ferring

Status: Enrolling

Conditions: Bladder Cancer

Treatments: Drug: ADSTILADRIN

Study type: Observational

Funder types: Industry

Identifiers

NCT06026332

000431

Details and patient eligibility

About

Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prescribed and scheduled treatment with ADSTILADRIN per physician discretion or received the first instillation of ADSTILADRIN per physician discretion after 5 September 2023 but prior to site activation
• Signed and dated ICF.
• Age 18 years or older at day ICF is signed.

Exclusion criteria

• Currently enrolled in a clinical trial.
• Participants who have previously been treated with ADSTILADRIN in the context of a clinical trial
• Participant is pregnant or breastfeeding.

Trial design

400 participants in 1 patient group

ADSTILADRIN

Treatment:

Drug: ADSTILADRIN